Osteoporosis Biosimilar OK’d; New Endo Guidelines; A Hot Spot for Stealing Ozempic

[ad_1]

(MedPage Today) — The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture and increasing bone mass in several patient populations, said maker Samsung Bioepis.
A group of 50…

[ad_2]

Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/114260

Author :

Publish date : 2025-02-18 20:35:34

Copyright for syndicated content belongs to the linked Source.